Clinical Trials
Aduro’s lead program, a combination immunotherapy comprised of its novel GVAX Pancreas and CRS-207 technologies, is being evaluated in a 240-patient Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer.

Aduro is harnessing the immune system to treat cancer.  Aduro's technologies are designed to activate both innate and adaptive immunity to generate a potent and long-lasting response against cancer.   

  • September, 10 2014  | Stephen Isaacs interviewed about Aduro's mesothelioma program  LISTEN TO IT HERE
  • July, 21 2014  | Aduro receives breakthrough therapy designation from FDA for innovative pancreatic cancer combination immunotherapy  READ IT HERE
  • July, 17 2014  | Aduro names industry veteran and academic leader, Gerald Chan, DSc to its board of directors  READ IT HERE
  • June, 11 2014  | Aduro secures $55 million Series C financing  READ IT HERE
  • June, 02 2014  | Aduro announces ASCO presentation of promising results from Phase 1b clinical trial of its novel immunotherapy for the treatment of mesothelioma  READ IT HERE
  • May, 29 2014  | Aduro announces license agreement with Johnson & Johnson Innovation for novel immunotherapies for prostate cancer  READ IT HERE
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use